Hisamitsu Of Japan Bids For Control Of U.S.-Based Noven
This article was originally published in PharmAsia News
Executive Summary
Japan's Hisamitsu Pharmaceutical said it intends to bid for total control of Noven Pharmaceuticals of the United States at an estimated cost of $430 million. Hisamitsu already owns a 5 percent stake in the U.S. company. Noven focuses on drug-deliver patches, a fit for Hisamitsu since it specializes in pain-relieving patches. Hisamitsu President Hirotaka Nakatomi said the purchase also would speed the firm's expansion in the United States. (Click here for more - a subscription may be required